Evidence map›Paper›PMID 41782805›Full record

ReviewRegenerative therapy2026

Can cell-based therapies bridge the gap between research and reality in the treatment of myocarditis? A systematic review and meta-analysis.

Ulugbek Yakhshimurodov, Kizuku Yamashita, Sho Komukai, Bekzod Isomitdinov, Takuji Kawamura, Shunsuke Saito, Shigeru Miyagawa

Abstract readReview
In one paragraph

Review in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ulugbek YakhshimurodovDepartment of Cardiovascular Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.
Kizuku YamashitaDepartment of Cardiovascular Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.
Sho KomukaiDepartment of Medical Data Science, Tokyo Medical University, Shinjuku, Tokyo, Japan.
Bekzod IsomitdinovWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
Takuji KawamuraDepartment of Cardiovascular Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.
Shunsuke SaitoDepartment of Cardiovascular Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.
Shigeru MiyagawaDepartment of Cardiovascular Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Myocarditis is a non-ischaemic myocardial injury caused by infectious agents, immune-mediated diseases, cardiotoxic drugs, and vaccines. Treatment options are largely supportive, with emphasis on close monitoring, exclusion of other diseases explaining symptoms, adherence to heart failure treatment recommendations, and consideration of etiology-directed interventions, if applicable, such as antiviral or immunosuppressive agents, steroids, discontinuation of antineoplastic therapy, and strategies to increase left ventricular (LV) ejection fraction (LVEF). In this context, cell-based therapies (CBTs) have emerged as a new therapeutic strategy and were believed to fill this gap. However, results were inconsistent across studies, which necessitates the need for rigorous systematic reviews to analyze available evidence comprehensively. Methods: The review protocol was registered on the PROSPERO website, and the study was conducted in accordance with PRISMA regulations. Searches were conducted in Embase, CINAHL Plus via EBSCO host, Web of Science, Scopus, and PubMed. A total of 60 original papers published between 2004 and 2022 in 48 peer-reviewed journals were included in the meta-analysis to determine the efficacy of CBTs on the LV fractional shortening (LVFS), LVEF, capillary density (CD), inflammatory cell infiltration rate (ICIR), and fibrotic area (FA). The risk of bias (RoB) and study quality were assessed using the SYRCLE RoB tool and CAMARADES checklist, respectively. As the preliminary assessment indicated substantial heterogeneity among the included studies, a random-effects model was applied to pool effect sizes. Subgroup analyses were performed to explore potential sources of heterogeneity across studies. Publication bias was assessed by visual inspection of funnel plots for asymmetry and statistically evaluated using Egger's regression test. Results: In total, the adapted and optimized search strategy retrieved 14,503 records from five databases. The majority of studies exhibited an unclear or high risk of bias in several domains, particularly selection bias and performance bias. Quality assessment revealed that only four studies (6.7%) were classified as high quality and four (6.7%) as low quality, while the remaining 52 studies (86.7%) were rated as moderate quality, with scores ranging from 4 to 6. CBTs improved LVFS (%) by 7.17 [95 % CI: 5.67, 8.66], LVEF (%) by 9.00 [95 % CI: 7.03, 10.97], CD (capillaries/mm Conclusion: Despite significant heterogeneity and moderate publication bias, the results were very encouraging, as reflected in the consistent effect directions across all studies in terms of cardiac function and histology. Overall, our results demonstrated the need for well-designed studies with adequate animal sample sizes, a standardized approach to reporting, and mechanistic investigations that directly link structural remodeling to functional recovery. Addressing these issues will be critical steps for conducting large-scale clinical trials.

Indexed as

Cell therapyDilated cardiomyopathyMeta-analysisMyocarditisSystematic review

Identifiers

PMID41782805
PMCPMC12955682

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.